Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. In an Aug. 14 research note, Dawson James Securities analyst Jason Kolbert reported that Soligenix Inc. (SNGX:NASDAQ) "is now focused on the two pivotal programs, i...
Streetwise Reports | August 22, 2019 |

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. In a Sept. 26 research note, Dawson James Securities analyst Jason Kolbert reported that IsoRay Inc. (ISR:NYSE.MKT) launched a new marketing campaign call...
Streetwise Reports | October 1, 2019 |

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. In a Dec. 2 research note, Dawson James Securities analyst Jason Kolbert purported that Anavex Life Sciences Corp.'s (AVXL:NASDAQ) ANAV...
Streetwise Reports | December 11, 2019 |

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...
Streetwise Reports | January 16, 2020 |

Three COVID-19 Patients Treated with PLX Cells

Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. In a March 30 research note, Dawson James Securities analyst Jason Kolbert reported that three high-risk COVID-19 pati...
Streetwise Reports | April 2, 2020 |

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infe...
Streetwise Reports | June 18, 2020 |

Coverage Initiated on 'Biotech Machine'

The compelling reasons behind those descriptors are explored in a Dawson James Securities report. In an Aug. 26 research note, analyst Jason Kolbert reported that DawsonJames Securities initiated coverage on Fortress Biotech Inc. (FBIO:NASDAQ) with a Buy rating and ...
Streetwise Reports | September 5, 2019 |

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure ...
Streetwise Reports | November 15, 2019 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |
1 2 3 4 5